1-(5-fluoropyrimidin-2-yl)-4-methyl-1H-[1,2,3]triazolo[4,5-c]pyridine

Catalog No. :
ACTZRS394
CAS No. :
2097603-70-6
Molecular Formula :
C10H7FN6
Molecular Weight :
230.21

IUPAC Name:1-(5-fluoropyrimidin-2-yl)-4-methyl-1H-[1,2,3]triazolo[4,5-c]pyridine

1-(5-fluoropyrimidin-2-yl)-4-methyl-1H-[1,2,3]triazolo[4,5-c]pyridine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg97%$453.00Login to see priceInquiryInquiry
1g97%$1133.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-(5-fluoropyrimidin-2-yl)-4-methyl-1H-[1,2,3]triazolo[4,5-c]pyridine
IUPAC Name1-(5-fluoropyrimidin-2-yl)-4-methyl-1H-[1,2,3]triazolo[4,5-c]pyridine
Molecular FormulaC10H7FN6
Molecular Weight230.21
SMILESCC1=NC=CC2=C1N=NN2C3=NC=C(F)C=N3
InChI KeyTZWFXCNSQJDROF-UHFFFAOYSA-N
Synonym1-(5-fluoropyrimidin-2-yl)-4-methyl-1H-[1,2,3]triazolo[4,5-c]pyridine;1H-1,2,3-Triazolo[4,5-c]pyridine, 1-(5-fluoro-2-pyrimidinyl)-4-methyl-
CAS No.2097603-70-6

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACTZRS394 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACXFEN753 route compound structure diagram
    ACXFEN75362802-42-0 In Stock
  4. Then
  5. ACTZRS394 route product structure diagram
    ACTZRS3942097603-70-6
Inquiry

2. ACTZRS394 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACKJRC046 route compound structure diagram
    ACKJRC04617573-84-1 In Stock
  4. Then
  5. ACTZRS394 route product structure diagram
    ACTZRS3942097603-70-6
Inquiry

Comments (0)